Clinical and angiographic outcome after coronary arterial stenting with the carbostent

Antoniucci, David; Bartorelli, Antonio L.; Valenti, Renato; Montorsi, Piero; Santoro, Giovanni Maria; Fabbiocchi, Franco; Bolognese, Leonardo; Loaldi, Alessandro; Trapani, Maurizio; Trabattoni, Daniela; Moschi, Guia; Galli, Stefano

doi:10.1016/s0002-9149(99)00874-7

Cited by 82 publications

(49 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[12][13][14][15][16] This result also correlates with a previous study that examined the early and six month clinical and angiographic outcomes of Helistent stent implantation. 6) Of note, almost half of the lesions in our study had complex characteristics (type B2 or type C were 45% and type A lesions were only 9.8%).…”

Section: Discussionsupporting

confidence: 86%

Early and Late Angiographic and Clinical Outcome Following Helistent Stent Implantation

et al. 2004

View full text Add to dashboard Cite

SUMMARYThere is still a lack of data on the influence of different stent designs on long-term restenosis rates and major adverse cardiac events (MACE) with the use of new antithrombotic regimens. We evaluated the midterm (6 months) clinical and angiographic and lateterm (2 years) clinical outcome of Helistent stent implantation.The study population consisted of 150 patients with high risk factor rates who had single or multivessel disease and had undergone coronary Helistent stent implantation with new antiplatelet regimens. The control coronary angiographies were done at 6 months and they were followed clinically to the end of 2 years.In 150 patients, 236 Helistent stents were implanted for 224 lesions. Helistent stent implantation was associated with a very high success rate (99%). The angiographic restenosis rate was 11.3% at 6 months. Only 16% of the patients experienced target lesion revascularization, 20% of the patients experienced MACE and of them, only 3.3% died at the end of two year follow-up period.The results demonstrate that the Helistent stent can be implanted with a high success rate with encouraging 6 month angiographic and late clinical outcomes. (Jpn Heart J 2004; 45: 1-10)

show abstract

Section: Discussionsupporting

confidence: 86%

Early and Late Angiographic and Clinical Outcome Following Helistent Stent Implantation

et al. 2004

View full text Add to dashboard Cite

show abstract

“…This higher diameter may have favored Penta™ stents, because a wider vessel could accommodate intimal hyperplasia more adequately. Nevertheless, if we focus on in-stent late loss, which is considered the measurement that best reflects the real and pure biological effect of coronary stent performance 24 , we will observe that late loss was similar between the two stents, of approximately 1 mm, a value that is comparable to that observed in previous studies with diamond-like carbon 18 , silicon carbide 25 and carbon-coated 26,27 stainless steel stents.…”

Section: Discussionsupporting

confidence: 71%

“…One of the theoretical advantages of diamond-like carbon coating is the lower incidence of acute or subacute thrombosis because of a better biocompatibility with low platelet activation 10,13,26,27 . The present study used the same antiplatelet therapy in both groups (aspirin and clopidogrel) for the same period (30 days).…”

Section: Discussionmentioning

confidence: 99%

Estudo comparativo randomizado do implante de Stent de aço inoxidável recoberto por carbono semelhante ao diamante versus não recoberto em pacientes com doença arterial coronariana

Meireles¹,

Abreu²,

Forte³

et al. 2007

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

show abstract

“…The Carbostent (Sorin Biomedica Cardio) is a metal stent coated with a carbon film that is thought to be less thrombogenic than uncoated steel stents. 8 Antoniucci et al 9 investigated the long-term biocompatibility of the Carbostent in a group of 112 patients with an intermediate risk of developing restenosis. Six-month follow-up revealed low MACE and restenosis rates of 12% and 11%, respectively.…”

Section: Stents Coated With Biocompatible Materialsmentioning

confidence: 99%

Coated Stents for the Prevention of Restenosis: Part II

2002

View full text Add to dashboard Cite

T his is the second part of a 2-part article that reviews the literature on coated stents and their effects on in-stent restenosis after percutaneous coronary intervention (PCI). Part I of this review discussed the pathophysiology of in-stent restenosis, specific stent coatings, and animal studies investigating coated stents. Part II discusses nonrandomized studies and clinical trials in humans. Studies in humans have examined stents coated with biocompatible materials and drug-eluting stents. Complications and controversies associated with this new technology are also addressed. Human StudiesThe risk of developing in-stent restenosis is related to a variety of factors, both clinical and procedural. [1][2][3][4][5][6][7] On the basis of these risk factors, patients enrolled in both nonrandomized studies and clinical trials have been classified as having a high, intermediate, or low risk of restenosis. Therefore, the binary restenosis rates (Ͼ50% diameter stenosis angiographically) and major adverse cardiac event (MACE) rates in human studies vary greatly depending on the overall risk profile of patients enrolled in these studies. Non-Randomized Studies Stents Coated with Biocompatible MaterialsThe biocompatibility of stents coated with several materials, including carbon, gold, silicon carbide, and phosphorylcholine, has been investigated in humans. The Carbostent (Sorin Biomedica Cardio) is a metal stent coated with a carbon film that is thought to be less thrombogenic than uncoated steel stents. 8 Antoniucci et al 9 investigated the long-term biocompatibility of the Carbostent in a group of 112 patients with an intermediate risk of developing restenosis. Six-month follow-up revealed low MACE and restenosis rates of 12% and 11%, respectively. A second study in another group of 112 patients at high risk for restenosis resulted in a MACE rate of 20% and a binary restenosis rate of 25% by 6 months. 10 These results suggest that the Carbostent is well tolerated in vivo and possibly inhibits neointimal hyperplasia, especially in high-risk patients (Table 1).Gold has been touted as a biocompatible material and has been thought to be ideal for coating coronary stents because of its radio-opaque properties. 1 Two studies evaluating the biocompatibility of gold-coated stents suggested equivalency with uncoated steel stents. 11,12 However, two other studies concluded that these stents may increase neointimal hyperplasia compared with uncoated stents, although patients at a higher risk for restenosis were enrolled. 13,14 Follow-up angiography at 6 months demonstrated a relatively high lumen late loss (postintervention minimum luminal diameter minus the minimum luminal diameter at follow-up) and diameter stenosis in both studies (Table 1). Overall, there have been conflicting results in observational studies examining goldcoated stents, and the restenosis rates seem to be no better than those obtained with uncoated steel stents.Silicon carbide is an inert semiconductor that can be coated onto prosthetic surfaces and has be...

show abstract

Clinical and angiographic outcome after coronary arterial stenting with the carbostent

Cited by 82 publications

References 14 publications

Early and Late Angiographic and Clinical Outcome Following Helistent Stent Implantation

Early and Late Angiographic and Clinical Outcome Following Helistent Stent Implantation

Estudo comparativo randomizado do implante de Stent de aço inoxidável recoberto por carbono semelhante ao diamante versus não recoberto em pacientes com doença arterial coronariana

Coated Stents for the Prevention of Restenosis: Part II

Contact Info

Product

Resources

About